Pemigatinib Approved for Cholangiocarcinoma

Often, fibroblast growth factor receptor (FGFR) 2 gene alterations occur in the pathogenesis of cholangiocarcinoma. The FDA recently approved an oral inhibitor of FGFR2, pemigatinib (PemazyreTM, Incyte Corporation), which has shown efficacy in patients with previously treated, locally advanced, or metastatic cholangiocarcinoma with and without FGFR2 gene alterations. FoundationOne®CDx was also approved as a companion diagnostic test for this indication.  FDA approval was based on a cli...
Continue reading

Aspirin and Biliary Tract Cancer Survival: Sarah Jackson, PhD

​Biliary tract cancers have a dismal prognosis, with five-year survival rates ranging from 5% to 15%. In their publication in JAMA Oncology, Sarah S. Jackson, PhD, and colleagues report that aspirin increases survival in biliary tract cancers, including gallbladder cancer, cholangiocarcinoma, ampulla of Vater cancer, and overlapping lesions of the biliary tract. In this interview with i3 Health, Dr. Jackson discusses the potential ramifications of her study's findings. What led you to pursue thi...
Continue reading

In Biliary Tract Cancers, Aspirin Increases Survival

​Researchers have now revealed that aspirin can increase the dismal survival chances for biliary tract cancers. Because these rare diseases may not produce symptoms until the later stages, 60% to 70% of patients with biliary tract cancers present with later-stage disease. Less than 10% have resectable tumors at the time of diagnosis, and 50% present with lymph node metastasis. As a result, the median survival is under a year, with five-year survival rates ranging from 5% to 15%. "There is a crit...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.